"By adding Auxilium's complementary commercial portfolio, we believe this transaction is aligned with our strategy of pursuing accretive, value creating growth opportunities," said Endo CEO Rajiv De Silva in the press release. At first, Auxilium was none too pleased with Endo's courtship. Auxilium's board adopted a poison pill in mid-September to give it enough time to weigh Endo's original offer against the QLT merger plan.